Application are invited for two posts of Research Assistant (i.e. one post Un-reserved and one post SC), to be filled purely on temporary basis at ICMR Hqrs. Office, New Delhi.
Post : Research Assistant
[adsense:336x280:8701650588]
The National Pharmaceutical Pricing Authority (NPPA) has begun scrutiny of such devices, even asking makers to log in every detail about their manufacture and cost. After cardiac stents, about 14 medical devices increasingly sold at inflated prices in hospitals could see price regulation in the months to come. The list includes orthopedic implants, intraocular lenses and artificial heart valves to consumables such as syringes, needles and catheters.
The prospect of a major change to the regulatory agency comes as drug makers are under fire for high prices, including Marathon Pharmaceuticals LLC, which said "stop" the launch of its drug Duchenne muscular dystrophy after American lawmakers questioned her $ 89,000 a year award.
The Union health ministry said it set tough targets to reduce infant and maternal mortality rates, which are already at a faster pace than the global rate.
Union Health Minister J P Nadda said for the first time that the ministry has made fighting diseases such as kalazar, measles and other targeted people. He said In terms of maternal and child health, I talked earlier that our rate of reduction of AMI, MMR and total fertility rate (TFR) is faster than the global rate .
For the first time in the budget, we focused on targeting diseases. We are committed to ensuring that the department is focused on results, targets and results. Only talk about this year, but until 2020-2025, he said.
They are very encouraging results. Now we have set up tough targets within ourselves (ministry). Under it, for IMR, till 2019, we will reduce it from 37 to 28. For MMR till 2020, we have set a target of reducing it from 167 to 100, the minister said.
Noting that stress has been given on non-communicable diseases (NCDs), Nadda said universal screening for hypertension, diabetes, cervical, breast and oral cancers will be started in 100 districts of the country this year.
There has been a significant increase of Rs 10,290 crore in the health budget (from last year). From Rs 37,061 crore it rose to 47,352 crore this year, which is a jump of 27, 77 percent, he said. There was a style of operation where the previous government used to present a budget and then reduce it. After arriving in the news, it was reduced, Nadda alleged.
Among the main concerns of the US pharmacy sector in India are the unpredictable IP environment, high tariffs and drug taxes, failure of regulatory data protection, access policies Discriminatory and non-transparent markets and the unpredictable environment for clinical research.
The National Pharmaceutical Pricing Authority (NPPA) made it mandatory for these facilities to disclose separately the cost of the stent when charging a patient. Medical facilities, including retailers and resellers of stents, should also display the price list of stents on a part of their premises that is easily accessible to anyone wishing to consult the same.
The medical device will soon be disconnected from the pharmaceutical sector so that it can draw a separate and definitive line with a framework facilitating regulatory framework, said Union Minister for Chemicals, Ananth Kumar at Indian Pharma and Indian Medical Devices International Conference in the city.
The cost of a drug eluting stent currently varies between Rs 24,000 and Rs 1.5 lakh and that of a bioresorbable stent is Rs 1.7 lakh to Rs 2 lakh. More than 95% of the stents used in India are drug elution.
The Food Safety and Standards Authority of India (FSSAI) will soon release a draft regulation for organic foods to ensure safety through the value chain through appropriate certification of these products, said a senior official.
The Drug Marketing and Manufacturing Association (DMMA) estimates that the nutraceutical industry is expected to experience annual growth of 16% (CAGR) over the next five years. With annual growth of about 20% over the past six years, the market for nutraceuticals in India is expected to double to Rs 26,764 crore by 2020.